Janssen submits EMA filing for bladder cancer treatment
Drug Discovery World
SEPTEMBER 14, 2023
8 On August 29, Janssen submitted a supplemental New Drug Application (sNDA) to the FDA seeking full approval of erdafitinib in this indication based on Cohort 1 of the Phase III THOR study. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2019; 381(4):338-348. Fernandez E, et al. J Clin Med.
Let's personalize your content